Fermion plots €30M Finland API site expansion

hanko
Fermion's Hanko site.

Finland’s Fermion plans to spend €30 million to expand an API plant in Hanko--its largest investment in company history--in a move to support current and future business and to meet “tightening regulatory requirements.”

Beginning this summer and wrapping up in Q2 2018, the project will add capacity for both standard and potent APIs, according to Fermion’s release. The expansion will add more than 100 metric tons of capacity to the site's current annual capacity of 300 metric tons, Fermion said in a release. Hanko is currently Fermion’s fourth largest plant. Upon completion, the expanded site also will have extra space for future equipment, the company said.

There is signficant expansion and consolidation in the CMO industry right now, and Fermion joins peers Recipharm and Olon in bulking up in the field. Last month, Swedish CDMO Recipharm inked a $205 million deal for India’s Kemwell, getting its first U.S. site and drug development operations in Sweden and India. The first portion of that deal--$85 million for Kemwell’s operations in Sweden and the Research Triangle Park, NC, drug development biz Cirrus Pharmaceuticals--closed Monday. It is awaiting regulatory approval to buy Kemwell's API business in India. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Recipharm also recently acquired a 74% stake in India’s Nitin Lifesciences for $102 million, getting three sterile injectables plants in that deal. 

In a separate move, Italian API maker Olon said this week it’ll join forces with competitor Infa following a buyout by its ownership group for an undisclosed sum.

- here's the release

Related Articles:
CDMO Recipharm strikes again with deal for India's Kemwell
Italian API maker Olon bulks up with deal for competitor

Read more on

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.